FDA Approval
PITTSBURGH, December 1, 2011 -
- Product also 'prequalified' by WHO as a second-line treatment option -
Mylan Inc.
GENEVA, November 30, 2011 -
Afixed-dose combination therapy to combat malaria, Eurartesim, (dihydroartemisinin-piperaquine) theproductof Italian research conducted bySigma-TauandMMV, approved by the European Medicines Agency (EMA)
Therapy with a simple dosage regimen, up to 3 tablets once a day for 3 days.
TIRAT CARMEL, Israel, November 27, 2011 -
- Evidence Sufficient to Support the Use of This Procedure With Normal Arrangements -
InSightec Ltd announced that NICE, the National Institute for Health and Clinical Excellence of the NHS in the UK, announced new favorable guidelines for the treatment of uterine fibroids using MR guided Focused Ultrasound.
LEXINGTON, Massachusetts, November 22, 2011 -
Approval Will Add Substantial Manufacturing Capacity for Rare Disease Products
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted regulatory filings with both the European Medicines Agency (EMA) and the U.S.
FDA Approves BELOTERO Balance: Success of a Promising Partnership Between Anteis and Merz Aesthetics
GENEVA and PLAN-LES-OUATES, Switzerland, November 21, 2011 -
BELOTERO Balance has now been approved by the US Food and Drug Administration (FDA) for injection into the mid-to-deep dermis to correct moderate-to-severe facial wrinkles and folds such as nasolabial folds.
More News
- CAPRELSA (vandetanib) Receives Positive CHMP Opinion in the European Union for Treating Advanced Medullary Thyroid Cancer
- IDEV Technologies Receives FDA Clearance for Its SUPERA VERITAS 6 French Stent Delivery System
- Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME Drug Eluting Stent
- Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
- Syneron Announces the Global Launch of the eTwo, a new Combination of Advanced Technologies for Facial Treatments
- Agendia Successfully Completes Bi-Annual FDA Inspection
- Synapse Biomedical Receives FDA Approval for NeuRx Diaphragm Pacing System (DPS) to Treat Amyotrophic Lateral Sclerosis (ALS)
- FDA Approves Shire’s FIRAZYR (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
- Global Crossing Announces Government Certification for PSN Services
- NICE Recommends OZURDEX(R), an Innovative Treatment for Retinal Vein Occlusion (RVO), a Common Cause of Vision Loss
- EMA Accepts EISAI’S License Extension Application for Zonegran (zonisamide) in Epilepsy
- INCIVO(R) Receives Positive Opinion From the Committee for Medicinal Products for Human use (CHMP) for the Treatment of Genotype-1 Hepatitis C Virus (HCV)
- Taiho Pharmaceutical Co., Ltd and Nordic Group BV Enter Into a Development and Commercialization Agreement for the Recently EMA Approved Anti-Cancer Drug Teysuno[TM] Covering the EU and Other Selected European Countries
- Shire plc: Lialda (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
- Sequana Medical Receives CE Mark Approval for the ALFApump System and Adds Key Executive to Team
- 23 Patients With Organ Confined Low Risk Prostate Cancer Have Been Treated in Clinical Trials Using the ExAblate(R) Non-Invasive Prostate Cancer System
- OMNIlife science, Inc. Announces PS Knee FDA Clearance
- FDA Approves Lazanda - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
- FDA Advisory Committee Strongly Recommends Approval and Self-Administration of FIRAZYR (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
- Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer
- Shire Receives VYVANSE(R) Paragraph IV Notice Letters
- Optimization of Cardiac Resynchronization Therapy Using Cheetah Medical's NICOM(R) Hemodynamic Monitoring System was Found to Lead to Improvement in Heart Failure Outcomes
- Abbott Receives U.S. FDA Approval for XIENCE nano(TM) to Treat Coronary Artery Disease in Small Vessels
- Shire Receives VYVANSE(R) Paragraph IV Notice Letter
- Premia Spine Acquires Assets of Impliant
- University of Chicago Researchers Find That BIOREACTANCE(R) Technology Provides Superior Accuracy for Monitoring Hemodynamics in Patients Suffering From Pulmonary Hypertension, Suggesting Pivotal Roles in Disease Management and in Research
- BridgePoint Medical Announced 510(k) Clearance for an Expanded Indication to Treat Coronary Chronic Total Occlusions
- New Planning Software to Make Advanced, Complex Treatments Possible for More Patients
- FDA's Decision to Lift Import Alert Paves the Way for Apotex's Oral Solid Dose Products to be Available Again for US Consumers; Company Moves Forward to Restore Pipeline of Shipments to the Local Market
- Expanded Indication Supported by Results from the CREST Trial, Which Demonstrated Similar Safety and Efficacy for Stenting and Surgery
- Less Than 1 mm in Diameter, the Camera is Used for Medical Endoscopic Procedures
- New Presentation of Cyanide Antidote Cyanokit(R) 5 g in a Single Vial Matches the Antidote Initial Dose
- Absorbable Bone Hemostat Matrix Cleared For Clinical Use and Sale in Europe and Canada
- First ever medical device therapy indicated as an alternative to chemotherapy for cancer
- First ever medical device therapy indicated as an alternative to chemotherapy for cancer
